Huang LW, Sun D, Link TM, et al. - Researchers sought to determine the prevalence as well as the incidence of fractures and also the clinical correlates of fractures in patients managed for aggressive B-cell non-Hodgkin lymphoma (NHL). They reviewed clinical characteristics and standard-of-care CT scans of 162 eligible patients. These patients had aggressive B-cell NHL, undergone first-line therapy with R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)-like regimens, and had CT scans pre- and post-treatment available for review. Before undergoing chemotherapy, 38 patients (28%) had prevalent fractures. New fractures occurred in 16 patients (10%) within 1 year post-treatment. Having a prevalent fracture was a strong predictor for developing a new fracture post-treatment. On the basis of these data, performing screening for fractures prior to treatment in aggressive B-cell NHL patients who undergo R-CHOP-like therapy was recommended, and patients with existing fractures should be considered for therapy to reduce risk of new fractures.